ClinicalTrials.gg
RecruitingNCT06845553Updated Aug 15, 2025

A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis Patients

A Phase 2 interventional study of Vutiglabridin and Placebo in Knee Osteoarthritis (Knee OA), sponsored by Glaceum. Recruiting at 1 site in South Korea. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Glaceum · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of — 13 open to participants now, 21 under way, 4 of them phase 3. Osteoarthritis, Knee · Korea, Republic of.

Planned enrollment
65th of 85
60 · median 124
Started
2025
with 4 others
Phase 2
14 of 96
1 open now
Primary completion
2026-07
later than 8 of 20 live
Registered
87th of 96
by date

Among the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, this one is the 65th largest by planned enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2025, is one of 14 in phase 2, reaches primary completion later than 8 of the 20 other live ones, and was the 87th registered.

Osteoarthritis, Knee

3,294 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

13 of the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, or all of them as a file.
02

Study summary

  1. Study Objective To Explore the Efficacy and Evaluate the Safety of Vutiglabridin in Knee Osteoarthritis Patients
  2. Background Glaceum Inc. has evaluated the safety, tolerability, and pharmacokinetic/pharmacodynamic properties of vutiglabridin in healthy subjects through its Phase 1 trials, and is planning to perform this Phase 2a trial to assess the efficacy and safety of vutiglabridin in Knee Osteoarthritis Patients
  3. Study Design and Protocol This study is a randomized, double-blind, placebo-controlled, parallel-group trial. Subjects deemed eligible to participate in this study based on the inclusion/exclusion criteria will be assigned a subject number and randomized to one of the 3 treatment groups - 1 group receiving a placebo - in a 1:1:1 ratio. Subjects will be randomized to double-blind treatments and will receive a once-daily oral dose of the investigational product for 26 weeks according to the study protocol. Several parameters (i.e., 100mm VAS, WOMAC pain subscale, X-ray, MRI, BMI) will be evaluated to assess the efficacy of vutiglabridin. Assessments including measurement of vital signs, 12-lead ECG, clinical laboratory test, pregnancy test, physical examination, and adverse event monitoring will be performed to evaluate the safety and tolerability of vutiglabridin. Blood samples will be collected for pharmacokinetic assessment.
03

Conditions studied

  • Knee Osteoarthritis (Knee OA)
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily agreed to participate in the study after being informed about the nature of the trial and has signed the form approved by the IRB.
  2. Adults aged 40 to 75 years at the time of screening.
  3. Meets the American College of Rheumatology (ACR) criteria for osteoarthritis and has symptoms lasting for more than 3 months requiring pharmacological treatment. Must have knee pain and radiographic evidence of osteophytes, with at least one of the following:

    • Age 50 or older
    • Morning stiffness less than 30 minutes
    • Crepitus on knee motion
  4. Has a Kellgren-Lawrence grade II or III in the knee joint on X-ray at the time of screening.
  5. Experiences a maximum pain of 50 mm or greater on the 100 mm VAS in activity over the past 24 hours at screening and baseline.
  6. For females, the following conditions apply:

    • For women of , the serum hCG pregnancy test at screening must be negative, confirming not pregnant.
    • Not currently breastfeeding.
    • Has undergone surgical sterilization (documented bilateral tubal ligation, bilateral tubal occlusion, bilateral oophorectomy, or hysterectomy), or is .

      • Definition of menopause:
    • For women over 50 years: 12 months of natural amenorrhea.
    • For women under 50 years: Serum FSH level over 40 IU/L and 12 months of natural amenorrhea.

Exclusion criteria

Exclusion Criteria:

  1. of 35.0 kg/m² or higher at screening.
  2. Developed a new disease within 4 weeks before screening or during the screening period, as judged by the investigator.
  3. Has arthritis in joints other than the knee.
  4. Has any other joint disease except knee osteoarthritis (e.g., secondary osteoarthritis due to trauma, congenital defects, calcium deposition diseases, rheumatoid arthritis, gouty arthritis, Paget's disease, systemic inflammatory disorders, chondrocalcinosis, hemachromatosis, inflammatory arthritis, avascular necrosis, etc.).
  5. Has a history of knee or other joint surgery.
  6. Has received injections in the affected knee before the administration of the study drug:

    • injections within 3 months (13 weeks) to the knee osteoarthritis area.
    • Short-acting hyaluronic acid injections within 3 months (13 weeks) to the knee osteoarthritis area.
    • Long-acting hyaluronic acid injections within 6 months (26 weeks) to the knee osteoarthritis area.
  7. Has received drug therapy for pain control or symptom improvement in the knee joint area within 4 weeks before study drug administration (opioid analgesics, non-opioid analgesics, topical capsaicin, NSAIDs, anticonvulsants, and other treatments like physical therapy, prolotherapy, herbal treatment, glucosamine, chondroitin).
  8. Expected to undergo surgery during the clinical trial period that may affect study completion or adherence to the clinical protocol.
  9. Has neuropathic pain or has taken neuropathic pain medications (gabapentinoids, SNRIs, tricyclic antidepressants) within 4 weeks before screening.
  10. Has a history of myocardial infarction, unstable angina, stroke, , or deep vein thrombosis within 3 months (13 weeks) before screening.
  11. Has any clinically significant untreated or unstable diseases of the liver, kidney, nervous system, immune system, respiratory system, endocrine system, blood/oncologic diseases, cardiovascular diseases, psychiatric disorders, neoplastic diseases, or any other conditions deemed unsuitable for participation by the investigator.
  12. For males, has a history of hypogonadism or known causes of hypogonadism (e.g., prostate cancer treatment), infertility, Klinefelter syndrome, or Kalman syndrome.
  13. Has used medications that can alter reproductive hormone levels (e.g., anabolic steroids, androgens, anti-estrogens, glucocorticoids, opiates, etc.) within 6 months (26 weeks) before screening.
  14. Has a history of organ transplantation.
  15. Has clinically significant liver dysfunction (e.g., or ALT more than 2.5 times the , total more than twice the upper limit of normal [except documented Gilbert's syndrome]) or kidney dysfunction ( \<60 mL/min).
  16. Tests positive for , Ab, Ag/Ab, or VDRL (RPR) at screening.
  17. Has a history of malignant tumors within the past 5 years (except for those with completely treated basal cell carcinoma, in situ carcinoma, thyroid cancer, or squamous cell carcinoma of the skin, based on the investigator's medical judgment).
  18. Has used systemic steroids for 7 or more consecutive days within 3 months (13 weeks) before screening.
  19. Has taken drugs including methotrexate or antimetabolites within 3 months (13 weeks) before screening.
  20. Taking drugs that are substrates of the breast cancer resistant protein (BCRP) (e.g., rosuvastatin, sulfasalazine) at screening (however, can be eligible if switched to a different drug in the same class).
  21. Has a history of alcohol or drug abuse within 2 years before screening or tests positive for substance abuse at screening (except for documented chronic pain treatment with prescribed medications approved by the investigator).
  22. Has participated in another clinical trial or bioequivalence study within 6 months (26 weeks) before the first dose and received medicinal products (except for placebo).
  23. Has a history of or allergic reactions to any components of the investigational medicinal product.
  24. Has lactose intolerance.
  25. Unwilling to use medically acceptable during the clinical trial period and for 90 days after the last dose.

    • Medically acceptable contraception includes:
    • Oral hormonal contraceptives for female partners of male subjects.
    • Intrauterine devices with proven pregnancy failure rate.
    • Surgical sterilization (e.g., vasectomy, tubal ligation, hysterectomy).
  26. Unwilling to donate sperm/eggs during the trial or for 90 days after the last dose.
  27. Deemed unsuitable for participation in the trial based on clinical laboratory results or other reasons determined by the investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Vutiglabridin 600 mg Multiple Dose

    Multiple oral dosing of Vutiglabridin 600 mg for 26 weeks

    Drug: Vutiglabridin

  • Experimental
    Vutiglabridin 1000 mg Multiple Dose

    Multiple oral dosing of Vutiglabridin 1000 mg for 26 weeks

    Drug: Vutiglabridin

  • Placebo comparator
    Placebo

    Multiple oral dosing of placebo

    Drug: Placebo

Interventions

  • DrugVutiglabridin

    Once-daily oral administration

    Also known as: HSG4112,2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol

  • DrugPlacebo

    Once-daily oral administration

06

What researchers measure

Primary outcomes

  1. Change from baseline in 100 mm VAS

    Change from baseline (Day 1) in the maximum pain experienced during daily activity in the past 24 hours, as assessed by the subject using a 100 mm VAS(Visual Analog Scale; 0=no pain, 100=pain as bad as you can imagine) , at Week 26 post-dosing.

    Time frame: From baseline to Week 26

Secondary outcomes

  1. Change from baseline in 100 mm VAS

    Change from baseline (Day 1) in the maximum pain experienced during daily activity in the past 24 hours, as assessed by the subject using a 100 mm VAS(Visual Analog Scale; 0=no pain, 100=pain as bad as you can imagine) , at Week 4,8,13 and 26 post-dosing.

    Time frame: From baseline to Week 4, 8, 13

  2. Change from baseline in 100 mm VAS (weight-bearing)

    Change from baseline (Day 1) in pain experienced during weight-bearing, as assessed by the subject using a 100 mm VAS, at Weeks 4, 8, 13, and 26 post-dosing.

    Time frame: From baseline to Week 4, 8, 13, 26

  3. Change from baseline in 100 mm VAS (at rest)

    Change from baseline (Day 1) in pain experienced at rest, as assessed by the subject using a 100 mm VAS, at Weeks 4, 8, 13, and 26 post-dosing.

    Time frame: From baseline to Week 4, 8, 13, 26

  4. Change from baseline in 100 mm VAS (at night)

    Change from baseline (Day 1) in pain experienced at night, as assessed by the subject using a 100 mm VAS, at Weeks 4, 8, 13, and 26 post-dosing.

    Time frame: From baseline to Week 4, 8, 13, 26

  5. Change from baseline in WOMAC pain subscale

    Change from baseline (Day 1) in the total WOMAC(Western Ontario and McMaster Universities Osteoarthritis Index) score and scores for each subscale (pain, function, and stiffness) as assessed by the subject, at Weeks 4, 8, 13, and 26 post-dosing.

    Time frame: From baseline to Week 4, 8, 13, 26

  6. Subjects who reached a score of 30 mm or less on the 100 mm VAS.

    The proportion of subjects who reached a pain score of 30 mm or less on the 100 mm VAS at Weeks 4, 8, 13, and 26 post-dosing, as assessed by the subject.

    Time frame: From baseline to Week 4, 8, 13, 26

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Jul 2026, 11 months later.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's planned 11 months is below that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Feb 25, 2025
StartEst.
Aug 19, 2025
Primary completionEst.
Jul 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06845553
Lead sponsor
Glaceum
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Aug 19, 2025 (estimated)
Primary completion
Jul 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 15, 2025

Study contacts

Jaejin Shin
Contact
jaejin@glaceum.com
+82-31-8002-2558

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion